- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01321515
Bioequivalency Study of Famciclovir 500 mg Tablets Under Fasted Conditions
January 19, 2018 updated by: Roxane Laboratories
A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Famciclovir Tablets Under Fasting Conditions
The objective of this study was to prove the bioequivalence of Famciclovir 500 mg Tablets under fasting conditions.
Study Overview
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Advanced Biomedical Research, Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening
Exclusion Criteria:
- Positive test for HIV, Hepatitis B, or Hepatitis C.
- Treatment with known enzyme altering drugs.
- History of allergic or adverse response to famciclovir, penciclovir or any comparable or similar product.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
bioequivalence determined by statistical comparison Cmax
Time Frame: 8 days
|
8 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Benno G Roesch, M.D., Advanced Biomedical Research
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2007
Primary Completion (ACTUAL)
July 1, 2007
Study Completion (ACTUAL)
July 1, 2007
Study Registration Dates
First Submitted
March 21, 2011
First Submitted That Met QC Criteria
March 22, 2011
First Posted (ESTIMATE)
March 23, 2011
Study Record Updates
Last Update Posted (ACTUAL)
January 23, 2018
Last Update Submitted That Met QC Criteria
January 19, 2018
Last Verified
January 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FAMC-T500-PVFS-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Herpes
-
GlaxoSmithKlineCompletedHerpes Zoster | Herpes Zoster VaccineCanada, Spain, Korea, Republic of, United Kingdom, France, Czechia
-
GlaxoSmithKlineCompletedHerpes Zoster | Herpes Zoster VaccineUnited States, Estonia, Canada
-
Ohio State UniversityCompletedHerpes Zoster DiseaseUnited States
-
Nearmedic Plus LLCCompletedHerpes Simplex | Herpes Genitalis | Herpes | Herpes Oral | Herpes Simplex 2Russian Federation
-
GlaxoSmithKlineCompletedHerpes Zoster | Herpes Zoster VaccineUnited States, Canada, Belgium
-
GlaxoSmithKlineCompletedHerpes Zoster | Herpes Zoster VaccineUnited States, Australia, Spain, Finland, Germany, Japan, Taiwan, Canada, Sweden, Korea, Republic of, Czechia, Hong Kong, Mexico, Italy, Brazil, Estonia, France, United Kingdom
-
Merck Sharp & Dohme LLCCompletedHerpes Zoster | Herpes Zoster-related Complications
-
EMSCompleted
-
Centrexion TherapeuticsTerminatedAcute-onset Herpes Zoster PainAustralia
-
NovartisCompletedRecurrent Genital HerpesAustralia
Clinical Trials on famciclovir
-
NovartisCompletedFamciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster InfectionHerpes Zoster | ChickenpoxUnited States, Costa Rica, Guatemala, Panama
-
Roxane LaboratoriesCompleted
-
NovartisCompleted
-
Teva Pharmaceuticals USACompleted
-
Teva Pharmaceuticals USACompleted
-
Novartis PharmaceuticalsCompletedGenital HerpesUnited States, Germany, Australia, Canada
-
NovartisCompleted
-
NovartisCompletedRecurrent Genital HerpesAustralia
-
Novartis PharmaceuticalsCompletedHerpes SimplexUnited States, Panama
-
NovartisCompletedGenital HerpesUnited States